Jeanie Wildes, NP
Primary Care · Sedona, AZNPI 1245390376
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Amgen at 41.6% of the total. Reporting peaked in 2022 at $371 and has fallen 59.4% since, to $151 in 2025.
Across 34 payments — averaging $27.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$394
- AbbVie$201
- Biohaven Pharmaceuticals, Inc.$67
- Exact Sciences$59
- Bayer$46
- Novo Nordisk$35
- plus $145 from 8 others
What the payments were for
- Food & beverage$93399%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $394 |
| AbbVie | 11 | $201 |
| Biohaven Pharmaceuticals, Inc. | 3 | $67 |
| Exact Sciences | 2 | $59 |
| Bayer | 2 | $46 |
| Novo Nordisk | 2 | $35 |
| Astellas Pharma US Inc | 1 | $27 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Pfizer | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| AstraZeneca | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$246
How this compares
$947 in reported general payments places this provider in the 65th percentile of 151 primary care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 63 | $82,123 |
| OxycontinOxycodone Hcl | 18 | $36,755 |
| OzempicSemaglutide | 29 | $27,710 |
| MounjaroTirzepatide | 18 | $24,644 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $20,064 |
| XareltoRivaroxaban | 15 | $18,828 |
| Repatha SureclickEvolocumab | 13 | $7,346 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $5,243 |
| Levothyroxine Sodium | 521 | $5,182 |
| PremarinEstrogens, Conjugated | 12 | $5,122 |
| Gabapentin | 151 | $3,412 |
| Estradiol | 70 | $3,287 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $3,156 |
| SynthroidLevothyroxine Sodium | 52 | $2,834 |
| Estradiol (Twice Weekly)Estradiol | 13 | $2,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $22 | $87,24575 claims |
| Novo NordiskOzempic | $35 | $27,71029 claims |
| Lilly USA, LLCMounjaro | $18 | $24,64418 claims |
| Johnson & JohnsonXarelto | $16 | $18,82815 claims |
| AstraZenecaSymbicort | $12 | $5,24314 claims |
| AbbVieSynthroid | $201 | $2,83452 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 151 primary care providers in Arizona.
Other primary care in Sedona
- Trey PowrzanasPhoenix$16K
- Christine Rocks-LopezPhoenix$14K
- Elena KlimovaPhoenix$8K
- Albert VillafaniaPhoenix$8K
- Daniela HaimovPhoenix$8K
- Lea NickolasAvondale$7K
- Neena VargheseSacaton$6K
- Katy DodtQueen Creek$5K
- Mercy GeorgeQueen Creek$5K
- Charity CorreaPhoenix$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.